Nonetheless, given the consensus that p38α is a driver of AD pathology, inhibitors of this isoform have been evaluated and show some promise in ameliorating tau hyperphosphorylation, synaptic decline, AD-associated neuroinflammation, and cognitive impairment [148,149]. The gene discussed is MAPT; the disease is Alzheimer disease.